多组分运动干预对患有帕金森病和轻度认知障碍的老年人的影响:一项随机对照研究
Yuanjiao Yan1, Yifei Xu2, Xiaoxia Wang3
1Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China; The School of Nursing, Fujian Medical University, Fuzhou, China.
概括
一个基于理论的多组分炼计划有效地改善了帕金森病和轻度认知障碍的老年人的运动和认知功能. 该干预措施显示出高可行性和坚持性,提供了一个有前途的治疗选择.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 康复医学 康复医学 康复医学
背景情况:
- 帕金森病 (PD) 通常涉及运动和认知能力下降,特别是在轻度认知障碍 (MCI) 患者中.
- 为PD-MCI优化运动干预措施需要进一步调查可行性和有效性.
研究的目的:
- 对患有PD-MCI的老年人进行基于理论的多组分运动干预措施的可行性和有效性进行评估.
- 为了比较干预组和积极对照组之间的结果.
主要方法:
- 随机对照试验与46名参与者 (每组23人) 超过12周.
- 干预组:基于理论的多组分练习;对照组:标准的帕金森病健康练习.
- 两组:60分钟的会议,每周3次.
主要成果:
- 高保留率 (95.7%) 和出席率 (99.6%的干预,99.5%的控制) 表明了极好的可行性.
- 与对照组相比,干预组在全球认知,执行功能,运动功能,平衡,步态,抑郁和生活质量方面显著改善.
- 没有报告任何不良事件.
结论:
- 基于理论的多组分运动干预是可行的,并且在患有PD-MCI的老年人中得到了很好的坚持.
- 这种干预有效地改善了这一群体的认知,运动和心理社会结果.
- 它代表了一个可行的治疗策略来管理PD-MCI.
更多相关视频
10:19Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease
Published on: August 22, 2014
14.2K
07:21Walk with Me Hybrid Virtual/In-Person Walking for Older Adults with Neurodegenerative Disease
Published on: June 16, 2023
876
相关概念视频
Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
